Results 121 to 130 of about 7,260 (279)
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar +35 more
wiley +1 more source
Comparison and an Improved Validation Optimistic Approach for Concurrency Control
Monika Patel, Dhiren B. Patel
openalex +1 more source
Objective Peripheral blood leukocyte telomere length (PBL‐TL) shortening is associated with systemic sclerosis–related interstitial lung disease (SSc‐ILD). However, its association with other organ involvement, disease severity, and survival remains unclear.
Monica M. Yang +6 more
wiley +1 more source
Adaptive conflict resolution for IoT transactions: A reinforcement learning-based hybrid validation protocol. [PDF]
Khaldy MAA +7 more
europepmc +1 more source
Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision. [PDF]
Mudimu E +8 more
europepmc +1 more source
Secure Decentralized IoT Service Platform Using Consortium Blockchain. [PDF]
Zhang R, Xu C, Xie M.
europepmc +1 more source
Transaction Management for Mobile Objects Using Optimistic Concurrency Control [PDF]
Atul Adya
openalex
Distributed Transactions for Google App Engine: Optimistic Distributed Transactions built upon Local Multi-Version Concurrency Control [PDF]
Daniel Shawcross Wilkerson +5 more
openalex +1 more source
Animal Models and Experimental Medicine, EarlyView.
Asian Federation of Laboratory Animal Science Associations (AFLAS)
wiley +1 more source
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo +15 more
wiley +1 more source

